Botulinum Toxin Treatment of Adductor Spasmodic Dysphonia: Longitudinal Functional Outcomes

被引:65
作者
Novakovic, Daniel [1 ]
Waters, Heather H. [2 ]
D'Elia, Joanna B. [1 ]
Blitzer, Andrew [1 ]
机构
[1] New York Ctr Voice & Swallowing Disorders, New York, NY USA
[2] Cleveland Clin Head & Neck Inst, Dept Otolaryngol Head & Neck Surg, Cleveland, OH USA
关键词
Spasmodic dysphonia; botulinum toxin; adductor; quality of life; treatment outcomes; dystonia; BLOCK NEUROTRANSMITTER RELEASE; LIFE V-RQOL; LARYNGEAL DYSTONIA; FOCAL DYSTONIA; INJECTIONS; EXPERIENCE; TETANUS; MOTOR;
D O I
10.1002/lary.21395
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: Laryngeal botulinum toxin (BoNT) injection is a well-established symptomatic treatment for adductor spasmodic dysphonia (AdSD). Injections may be followed by a period of muscle weakness characterized by breathiness, voice weakness, and dysphagia for liquids. A recent study described some detriment and limited functional improvement with "good voice" for only one-third of the period between successive injections. Our objective was to examine the longitudinal effect of BoNT treatment for AdSD upon functional outcomes and quality of life when using a patient-specific dosing regimen. Study Design: Prospective cohort study. Methods: Patients presenting for BoNT treatment of AdSD were asked to complete evaluation of voice function after each injection using the percentage of normal function (PNF) scale (daily for two weeks, then weekly). Other parameters measured included voice handicap index (VHI), duration of effect, and complications. Results: A total of 133 patients treated continuously between January 2006 and January 2009 with an individuated regime (dose, pattern, and schedule) were included. Of 1,457 treatments, 50.9% experienced some breathiness. Mean VHI improvement was 9.6%. Mean PNF improvement was 30.3%. There was correlation between the two scales. Dysphagia to liquids was reported after 14.2% of treatments. We describe two distinct types of functional outcome curve. A total of 28.5% of treatments were followed by initial functional decline. Mean time below baseline function was 5.7%. Mean proportion of time in plateau phase was 42.5%. Conclusions: It is important to consider longitudinal functional outcomes in BoNT treatment of AdSD. An individuated dosing regimen helps minimize side effects and maximize functional and quality-of-life outcomes.
引用
收藏
页码:606 / 612
页数:7
相关论文
共 21 条
[11]   The mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site [J].
Giladi, N .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 152 (02) :132-135
[12]   Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia [J].
Hogikyan, ND ;
Wodchis, WP ;
Spak, C ;
Kileny, PR .
JOURNAL OF VOICE, 2001, 15 (04) :576-586
[13]  
Holzer SES, 1996, LARYNGOSCOPE, V106, P86
[14]   How botulinum and tetanus neurotoxins block neurotransmitter release [J].
Humeau, Y ;
Doussau, F ;
Grant, NJ ;
Poulain, B .
BIOCHIMIE, 2000, 82 (05) :427-446
[15]   Longitudinal Follow-Up of Adductor Spasmodic Dysphonia Patients After Botulinum Toxin Injection: Quality of Life Results [J].
Paniello, Randal C. ;
Barlow, Jamie ;
Serna, Jannie S. .
LARYNGOSCOPE, 2008, 118 (03) :564-568
[16]  
ROSALES EL, 1996, MUSCLE NERVE, V19, P488
[17]   Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia - part II [J].
Rubin, AD ;
Wodchis, WP ;
Spak, C ;
Kileny, PR ;
Hogikyan, ND .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2004, 130 (04) :415-420
[18]   TETANUS AND BOTULINUM-B NEUROTOXINS BLOCK NEUROTRANSMITTER RELEASE BY PROTEOLYTIC CLEAVAGE OF SYNAPTOBREVIN [J].
SCHIAVO, G ;
BENFENATI, F ;
POULAIN, B ;
ROSSETTO, O ;
DELAURETO, PP ;
DASGUPTA, BR ;
MONTECUCCO, C .
NATURE, 1992, 359 (6398) :832-835
[19]  
Sulica L, 2009, NEUROLOGICAL DISORDE, P196
[20]   Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients - an Australian experience [J].
Tisch, SHD ;
Brake, HM ;
Law, M ;
Cole, IE ;
Darveniza, P .
JOURNAL OF CLINICAL NEUROSCIENCE, 2003, 10 (04) :434-438